Piramal Pharma Ltd

Piramal Pharma Ltd

Deutsche Bank AG has made a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, regarding the creation of an encumbrance over 98,400,000 equity shares of Piramal Pharma Limited, constituting 7.39% of the total issued and paid-up share capital of the company.

Piramal Pharma Ltd

Piramal Pharma Ltd has released its Sustainability Report for FY2025-26, highlighting its progress in sustainability and responsible business practices.

Piramal Pharma Ltd

Piramal Pharma Ltd has acquired an additional 40.67% stake in Yapan Bio Private Limited, increasing its shareholding to 74.00% and making Yapan a subsidiary of the company.

Piramal Pharma Ltd

Piramal Pharma Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from Deutsche Bank AG, Hong Kong Branch, regarding the release of encumbrance over 98,400,000 equity shares of Piramal Pharma Ltd, constituting 7.39% of the total issued and paid-up share capital of the company.

Piramal Pharma Ltd

Piramal Pharma Ltd has exercised its call option to acquire an additional 41% equity stake in Yapan Bio Private Limited, an associate company, from existing shareholders. The final terms of the acquisition, including the acquisition consideration and effective date of transfer of shares, are yet to be finalized.

Piramal Pharma Ltd

Piramal Pharma Ltd has announced the schedule of analyst/institutional investor meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Piramal Pharma Ltd

Piramal Pharma Ltd has resumed operations at its facilities in Ahmedabad, Gujarat, after a temporary suspension due to heavy rainfall and flooding. The company has completed a preliminary assessment and initiated an insurance claim process, with no expected material impact on operations or financial performance.

Piramal Pharma Ltd

Piramal Pharma Ltd has made available the transcript of its earnings call on unaudited financial results for the quarter ended 30th June, 2026, on its website.

Piramal Pharma Ltd

Piramal Pharma Ltd held its 6th Annual General Meeting (AGM) on July 30, 2026, through video conferencing. The meeting was chaired by Ms. Nandini Piramal, and the requisite quorum was present. The AGM transacted the business mentioned in the notice dated June 5, 2026, and all resolutions were passed with the requisite majority. The meeting was webcast live on the e-voting website of National Securities Depository Limited (NSDL).

Piramal Pharma Ltd

Piramal Pharma Ltd held its 6th Annual General Meeting (AGM) on July 30, 2026, where all proposed resolutions were passed with a majority. The meeting was conducted through video conferencing, and remote e-voting was provided to members. The company's audited financial statements for FY 2025-26 were adopted, and key executives and auditors were present at the meeting.

Piramal Pharma Ltd

Piramal Pharma Ltd has released the audio recording of a conference call held on 30th July, 2026, discussing the unaudited financial results for the quarter ended 30th June, 2026. The recording is available on the company's website.

Piramal Pharma Ltd

Piramal Pharma Ltd has announced its Q1 FY27 results, showing a 17% revenue growth, with EBITDA increasing by 72% and EBITDA margin expanding by 400 basis points to 12.5%. The company's CDMO business delivered broad-based growth, while the Complex Hospital Generics business maintained leadership in key therapies and gained traction in ex-US inhalation anesthesia markets.

Piramal Pharma Ltd

Piramal Pharma Ltd has announced its Q1 FY27 results, with revenue growth of 17% and EBITDA margin expansion of 72% due to improved operating leverage and execution.

Piramal Pharma Ltd

Piramal Pharma Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, with revenue from operations at Rs. 1,124.95 crores, a decrease from Rs. 1,489.06 crores in the previous quarter. Net profit after tax was Rs. 113.48 crores, with basic EPS at Rs. 0.85.

Piramal Pharma Ltd

Piramal Pharma Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, with revenue from operations at Rs. 1,124.95 crore and net profit after tax at Rs. 113.48 crore.

Piramal Pharma Ltd

Piramal Pharma Ltd has granted 56,36,436 stock options under the Employee Stock Option and Incentive Plan 2022 to its employees, with vesting and exercisability conditions specified.

Piramal Pharma Ltd

Piramal Pharma Ltd has temporarily suspended operations at its manufacturing facilities in Ahmedabad, Gujarat, due to heavy rainfall and flooding, but the company's insurance policies cover the assets and the facilities account for less than 3% of consolidated revenues.

Piramal Pharma Ltd

Piramal Pharma Ltd. has issued a clarification in response to a news article on NDTV Profit regarding a sudden spike in its share price. The company stated that the referenced news article does not contain any new material information requiring disclosure under SEBI Listing Regulations. Piramal Pharma affirmed that all relevant company information is already in the public domain, and no material events remain undisclosed. The company attributed the share price movement to market dynamics and is unaware of any specific reason driving the rally.

Piramal Pharma Ltd

The BSE has sought clarification from Piramal Pharma Ltd on June 23, 2026, in reference to news that appeared on NDTV Profit on the same date. The announcement from the company merely states that clarification has been sought by the exchange, without providing details of the specific news content that prompted the query. This is a procedural request from the exchange.